Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

IMMURON (IMRN) vs XTL Biopharmaceuticals Ltd. (XTLB)

IMMURON and XTL Biopharmaceuticals Ltd. are both Biotechnology companies. IMMURON and XTL Biopharmaceuticals Ltd. are of similar size ($9.7M and $9.6M). IMMURON grew revenue faster over the last twelve months: −6.62% against −12.7%. XTL Biopharmaceuticals Ltd. has the higher net margin (0.00% vs −262.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 10 metrics below, IMMURON leads on 7 and XTL Biopharmaceuticals Ltd. on 3.

Valuation

Metric IMRN XTLB Biotechnology median
P/E n/m n/m 7.88
P/S n/m 1.53 11.47
P/B n/m n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.93 n/m 0.74
EV/Sales (3.50) 1.44 10.73
Earnings yield (1.75%) (12.73%) (28.84%)
Free cash flow yield 0.00% (124.05%) (23.03%)

Profitability

Metric IMRN XTLB Biotechnology median
Gross margin 71.28% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin (262.71%) 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% 0.00% (57.72%)
Return on assets 0.00% 0.00% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IMRN XTLB Biotechnology median
Revenue growth (TTM) (6.62%) (12.71%) 5.64%
EPS growth (last fiscal year) 37.29% (159.17%) —
Revenue growth, 5-year CAGR 116.96% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMRN XTLB Biotechnology median
Debt to equity 0.00 (1.83) 0.00
Current ratio 7.17 0.70 4.73
Net debt to EBITDA 2.25 (0.11) 0.96

Dividend

Metric IMRN XTLB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IMRN XTLB Biotechnology median
Market cap 9.60m 9.66m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack